I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

Cure SMA 2025

-
Coming soon
11:30 PM
Duration 120mins Anaheim, USA
Baseline demographics, clinical characteristics and treatment patterns of risdiplam▼-treated individuals with SMA from the (PNCR) registry
B T Darras, S Roumpanis, W Martens, S Shapouri, T Dickendesher, C J Guittari, J W Day, R S Finkel, M Hirano, D Jayaraman, Z Zolkipli-Cunningham, S Edwards

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 120mins Anaheim, USA
Real-world risdiplam▼ effectiveness in adults with SMA from the Pediatric Neuromuscular Clinical Research (PNCR) registry
D Jayaraman, S Roumpanis, W Martens, T Dickendesher, S Shapouri, B T Darras, M Hirano,Z Zolkipli-Cunningham, A Gershon

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 120mins Anaheim, USA
Delphi consensus project to determine the meaningful treatment outcomes in adult SMA
K Sully, CA Chiriboga, T Duong, Y Erbas, J Glascock, N Gusset, R Muni-Lofra, C O'Connell, JF Vázquez-Costa, MC Walter, CJ Guittari, J Cochrane,LD Townson, A Marciniak, D Riley, C Gasser

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 120mins Anaheim, USA
Clinical outcomes among risdiplam▼-treated patients with spinal muscular atrophy (SMA) in the Cure SMA Clinical Data Registry
S Shapouri, TM To, S Whitmire, L Belter, M Schroth, TL Dickendesher, S Tam, R Schuldt

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 120mins Anaheim, USA
Examination of outcomes data for risdiplam▼-treated individuals with SMA using the Cure SMA Community Update Survey
TM To, R Schuldt,TL Dickendesher, S Tam, S Shapouri

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
08:00 PM
Duration 120mins Anaheim, USA
International evidence-based consensus on the management of gastrointestinal adverse events related to the use of risdiplam▼ in patients with spinal muscular atrophy
Manisha K Korb and Channa Hewamadduma on behalf of the SMA Delphi Panel

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 120mins Anaheim, USA
Defining the clinical benefits of disease-modifying therapy in people living with spinal muscular atrophy who are permanently ventilated: a UK-based Delphi consensus process
Mariacristina Scoto on behalf of the SMA Delphi Panel

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 120mins Anaheim, USA
Real-world use of risdiplam▼ for the treatment of SMA in infants under 2 months of age
N Goedeker, VJ Carson, S Bernes, CC Haws, C Zaidman, C Campos, I Yermilov, MS Broder, E Chang, S Edwards, TL Dickendesher, S Tam, S Shapouri

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 120mins Anaheim, USA
A long-term follow-up study of risdiplam▼ (WeSMA study): Interim results in adult participants with SMA
Abdul Hamid, K Arya, S Bernes, JL Chinarian, CA Chiriboga, AK Daunter, S Dixon, A Kumar, S Ladha, SE Matesanz, LM Ramos-Platt, RC Richardson, ​RJ Scharf, MD Svoboda, DN Toupin, AS Varadhachary, V Vedanarayanan, SE Wright, I Tanvir, E Lim, E Keto, S Shapouri, R Shah, G Seth​

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
10:20 PM
Duration 20mins Disney's Grand Californian Hotel
Retrospective assessment of feeding and nutrition after 2 years of risdiplam▼ treatment in younger children with SMA using the CEDAS
G Baranello, E Conway ,Y Li, K Gorni

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
11:00 PM
Duration 120mins Anaheim, USA
The comparative efficacy and safety of risdiplam▼ versus high-dose nusinersen in children with Type 1 SMA
C Gasser, C Kokaliaris, N Hawkins, A Mahajan, D Alexander Scott, C. E Sideris

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 120mins Anaheim, USA
HINALEA 2: Baseline observations in a trial evaluating risdiplam▼ in patients with SMA who experienced a plateau or decline in function after gene therapy
CJ Guittari, A Hahn, K Kotulska-Jozwiak, E Keto, K Gorni, Y Li

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar